Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kobe, Yuen"'
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-12 (2022)
A high-throughput cell-based platform is developed for systematic investigation of receptor-ligand interactions and applied to identify cell-surface proteins that bind to SARS CoV-2.
Externí odkaz:
https://doaj.org/article/5dba194ff58e4aaabcc8abecee7d4c75
Autor:
Andrew Wallace, Deepali Rishipathak, Mahesh Yadav, Sanjeev Mariathasan, Evan W Newell, Alessandra Nardin, Oliver A Zill, Michael Fehlings, Leesun Kim, Xiangnan Guan, Kobe Yuen, Alireza Tafazzol, Shomyseh Sanjabi, Siming Ma, Ana Milojkovic
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background A growing body of evidence suggests that T-cell responses against neoantigens are critical regulators of response to immune checkpoint blockade. We previously showed that circulating neoantigen-specific CD8 T cells in patients with lung ca
Externí odkaz:
https://doaj.org/article/1b1d22e3dd284708b9bfcaa707c18a5e
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f20f4e26dac7ce017a501823fa9fa0
https://doi.org/10.1158/1078-0432.22480052.v1
https://doi.org/10.1158/1078-0432.22480052.v1
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Purpose:Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13798053ba75b9ddf6160ccc2387be26
https://doi.org/10.1158/1078-0432.c.6530360.v1
https://doi.org/10.1158/1078-0432.c.6530360.v1
Autor:
Kobe Yuen
Publikováno v:
Bio-Protocol, Vol 7, Iss 6 (2017)
Protein kinase R (PKR) is one of the key RNA-activated sensors for innate immunity. PKR is activated by pathogenic or aberrant RNAs such as short double-stranded RNAs or those with imperfect secondary structures, as well as a reduction in the amount
Externí odkaz:
https://doaj.org/article/9901cfc8d7e547f1a74502416574bef2
Autor:
Michael, Fehlings, Leesun, Kim, Xiangnan, Guan, Kobe, Yuen, Alireza, Tafazzol, Shomyseh, Sanjabi, Oliver A, Zill, Deepali, Rishipathak, Andrew, Wallace, Alessandra, Nardin, Siming, Ma, Ana, Milojkovic, Evan W, Newell, Sanjeev, Mariathasan, Mahesh, Yadav
Publikováno v:
Journal for immunotherapy of cancer. 10(8)
A growing body of evidence suggests that T-cell responses against neoantigens are critical regulators of response to immune checkpoint blockade. We previously showed that circulating neoantigen-specific CD8 T cells in patients with lung cancer respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::36be8095e7cf8d0c02124060c9a16874
https://pubmed.ncbi.nlm.nih.gov/35981786
https://pubmed.ncbi.nlm.nih.gov/35981786
Autor:
Svetlana Lyalina, Guadalupe Ortiz-Munoz, Kobe Yuen, Ira Mellman, Sanjeev Mariathasan, Matthew Albert, Deepti Nagarkar, Christine Moussion
Publikováno v:
Cancer Research. 83:4439-4439
Although gamma-amino butyric acid (GABA) is well characterized as the primary inhibitory neurotransmitter of the central nervous system, its role in the periphery as an immunomodulatory agent is not well understood. Given the widespread use of GABA-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::907f36b7c9fb7de8e747a29fa4bf1049
https://doi.org/10.1158/1538-7445.am2023-4439
https://doi.org/10.1158/1538-7445.am2023-4439
Autor:
Christopher Sweeney, Chang Xu, Jie He, Amanda Young, Alexander Robertson, Russell Petry, Daniel Zollinger, Alexander Fine, Neil Peterman, Eliana Polisecki, Tyler Warner, Kobe Yuen, Yanmei Huang, Zoe Assaf, Ryon Graf, Sanjeev Mariathasan, Priti Hegde, David Fabrizio, Thomas Powles
Publikováno v:
Cancer Research. 83:3362-3362
Introduction: IMbassador250 was a prospective phase III international multicenter trial enrolling 759 men with mCRPC who had prior progression on abiraterone, with or without prior taxane, randomizing to enzalutamide +/- atezolizumab. For this retros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30e035ae5cc215fe86c0b0b974fd7e4a
https://doi.org/10.1158/1538-7445.am2023-3362
https://doi.org/10.1158/1538-7445.am2023-3362
Autor:
Mahrukh A, Huseni, Lifen, Wang, Joanna E, Klementowicz, Kobe, Yuen, Beatrice, Breart, Christine, Orr, Li-Fen, Liu, Yijin, Li, Vinita, Gupta, Congfen, Li, Deepali, Rishipathak, Jing, Peng, Yasin, Şenbabaoǧlu, Zora, Modrusan, Shilpa, Keerthivasan, Shravan, Madireddi, Ying-Jiun, Chen, Eleanor J, Fraser, Ning, Leng, Habib, Hamidi, Hartmut, Koeppen, James, Ziai, Kenji, Hashimoto, Marcella, Fassò, Patrick, Williams, David F, McDermott, Jonathan E, Rosenberg, Thomas, Powles, Leisha A, Emens, Priti S, Hegde, Ira, Mellman, Shannon J, Turley, Mark S, Wilson, Sanjeev, Mariathasan, Luciana, Molinero, Mark, Merchant, Nathaniel R, West
Publikováno v:
Cell reports. Medicine.
Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) as a correlate of poor response to atezolizumab (anti-PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bcbbc350b5cf438cceeb2d1bb3b0f44b
https://pubmed.ncbi.nlm.nih.gov/36599350
https://pubmed.ncbi.nlm.nih.gov/36599350
Autor:
Christopher Sweeney, Ryon Graf, David Fabrizio, Kobe Yuen, Matthew J. Wongchenko, Pratyush Gupta, Priti Hegde, Geoffrey R. Oxnard, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:LBA249-LBA249
LBA249 Background: IMbassador250 was a prospective phase III international trial which showed no overall survival (OS) benefit for adding atezolizumab to enzalutamide for men with mCRPC who had prior progression on abiraterone. We hypothesized that g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8282aa44a0055f0e6f7b2ea672c642f5
https://doi.org/10.1200/jco.2023.41.6_suppl.lba249
https://doi.org/10.1200/jco.2023.41.6_suppl.lba249